Irah . Pastan - Cancer Science

Author Information

Ira H. Pastan is a distinguished researcher affiliated with the Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. His work primarily focuses on cancer research, with an emphasis on the development and application of immunotoxins for cancer therapy.

Research Contributions

Ira H. Pastan has made significant contributions to the field of cancer research, particularly in the development of immunotherapy-based treatments. His recent works include studies on the effectiveness of immunotoxins targeting transferrin receptors in breast cancer, glypican-1 (GPC1) in pancreatic cancer, and mesothelin in pancreatobiliary and other solid tumors. His research has also explored the application of immunotherapy in treating cholestatic liver fibrosis and the long-term outcomes of immunotoxin treatments in relapsed/refractory hairy cell leukemia patients.

Aliases

Ira H. Pastan is also known by several aliases including I Pastan, Ira Pastan, Ira H Pastan, Ira H. Pastan, Irah . Pastan, and I. Pastan.

Publication and Citation Metrics

Metric	Value
Citation Count	106,079
h-index	154
Paper Count	1,552

Publications:

Abstract P5-08-03: Intraductal administration of a Transferrin Receptor-directed immunotoxin eliminates ductal carcinoma in situ in preclinical mammary in-duct (MIND) models of breast cancer

DOI: 10.1158/1538-7445.sabcs21-p5-08-03

Year: 2022

GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling.

DOI: 10.1158/1535-7163.MCT-21-0778

Year: 2022

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.

DOI: 10.1200/JCO.2021.39.15_SUPPL.3051

Year: 2021

Indirect podocyte injury manifested in a partial podocytectomy mouse model.

DOI: 10.1152/ajprenal.00602.2020

Year: 2021

Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis

DOI: 10.1073/pnas.2101270118

Year: 2021

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.

DOI: 10.1200/JCO.2021.39.3_SUPPL.TPS452

Year: 2021

Immunotoxins: From Design to Clinical Application

DOI: 10.3390/biom11111696

Year: 2021

Cell culture

DOI: 10.1049/pbcs063e_appendixe

Year: 2021

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

DOI: 10.1186/s13045-020-01004-y

Year: 2021

Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia

DOI: 10.1080/10428194.2021.1929959

Year: 2021

How is Gene Therapy Administered?

What Are Immunotherapies?

What are the Common Reasons for Claim Denial?

How Does Poor Ventilation Affect Cancer Patients?

What Questions Should I Ask My Doctor?

Are There Any Side Effects of Targeted Therapies?

Can Nutrition Play a Role in Side Effect Management?

What are the diagnostic challenges in patients with both TB and cancer?

Which Cancers Can Be Treated with CAR T Cell Therapy?

What Are the Mechanisms Behind Lactobacillus' Anticancer Effects?

Partnered Content Networks

Relevant Topics